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Effect of cell density on intracellular adriamycin
concentration and cytotoxicity in exponential and plateau
phase EMT6 cells
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Summary The relationship between cell number and available Adriamycin (ADM) has been investigated in
EMT6 cells. Results have shown that the ratio between cell number and total available ADM is important in
determining in vitro ADM uptake and surviving fraction. Having established this effect, the sensitivity of
exponentially growing and plateau phase EMT6 cells to ADM was investigated. ADM was assayed by
extraction followed by spectrofluorimetry and also by flow cytometry (FCM); both methods were found to
give the same ratio of intracellular ADM between exponentially growing and plateau phase cells. We found
that for a given exposure dose plateau phase cells were more sensitive than exponentially growing cells. For
the same dose per cell, plateau cells take up more ADM than exponentially growing cells. But for a given
intracellular ADM concentration exponentially growing cells have a lower surviving fraction than plateau
phase cells. We conclude that the surviving fraction is dependent on the proliferative state of the cells and in
order to draw that conclusion it is important to relate the ADM effect on cells in vitro to the total ADM
available to each cell.
Flow cytometry (FCM) has been used to measure
intracellular Adriamycin (ADM) in cells cultured in
monolayer (Bhuyan et al., 1981, Durand & Olive,
1981, Ganapathi et al., 1982), suspension cultures
(Durand & Olive, 1981, Ganapathi et al., 1982,
Krishan & Ganapathi, 1980, Sutherland et al.,
1979) and in spheroids (Durand, 1981). We have
used FCM and cell survival assays to investigate
the response of exponentially growing and plateau
phase monolayer EMT6 cultures to ADM.
A number of problems are associated with FCM
measurement of ADM fluorescence (Durand &
Olive, 1981) and two particular problems are
encountered when attempting to compare
exponentially growing and plateau phase cells. The
first is that exponential and plateau phase cultures
have different monolayer densities. The second is
whether FCM measurement of ADM fluorescence
from exponentially growing and plateau phase
EMT6 cells are quantitatively comparable. Durand
(1981) has mentioned that cell density may effect
cytotoxicity; we have investigated the effect of cell
density on the amount of ADM measured in the
cell after treatment. Sutherland et al. (1979) have
published data from exponentially growing and
plateau phase EMT6 cells but only for a small
range of ADM doses. In this paper we have used a
greater dose range and also an equivalent range in
terms of ADMjug per cell for both exponentially
growing and plateau phase cells. We have also
compared the fluorescence emissions of ADM in
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exponentially growing and plateau phase cells with
results obtained by extraction of the drug with an
organic solvent.
Having systematically examined the effect of cell
density, we have been able to relate ADM content
as measured by FCM in exponentially growing and
plateau phase cultures to surviving fraction and
draw some conclusions as to the sensitivity of the
cells to ADM.
Materials and methods
Drug
Adriamycin was obtained from Montedison
Pharmaceuticals Ltd (England) as a freeze dried
powder with lactose. The drug was dissolved in
PBS and stored at -20°C as 500Mgml -1 stock
solution for a maximum of 2 months. Aliquots
were thawed out as required and diluted
appropriately with PBS.
Cell culture
The cells used in all experiments were EMT6/CC
details of which have previously been published
(Twentyman et al., 1975). Sterilin 25cm2 tissue
culture flasks were seeded with 105 cells and 5ml of
Eagles MEM supplemented with Earles salts plus
20% newborn calf serum, glutamine and antibiotics
were also added. Flasks were kept in a LEEC
automatic flow through gassing incubator, set at
7% CO2 93% air and 37°C. Exponentially growing
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cells were harvested on day 2, plateau phase cells
on day 7. The medium of the plateau phase
cultures was renewed daily from the fourth day
after seeding.
Cell concentration experiments
Experiments were devised to investigate whether
cell number had an effect on ADM fluorescence
and clonogenic fraction.
Exponentially growing EMT6 cultures, 2 days
post seeding, contain -3 x 105 cells per flask,
plateau phase cultures - 107 per flask. Differences
in response to a drug may be interpreted as due to
the different proliferative status of the cells but may
also be due to differences in the amount of ADM
available per cell. In order to change cell
concentration without altering proliferative status in
the monolayer system, we decided to keep the cell
number per flask and drug concentration constant
and alter the volume of medium containing drug
added to the cells.
Exponentially growing cell cultures were prepared
as described above. The medium was removed and
fresh medium containing ADM at 2jugml -1 was
added in volumes of 0.5, 1, 2, 3, 5 and lOml. A
control experiment was carried out where cells
received the same volumes of medium but without
drug. Cultures with and without drug were
incubated for 1 h at 37°C. Following exposure to
the drug the medium was removed, the monolayer
rinsed twice with 0.1% trypsin and incubated at
37°C for 15min. The cells were resuspended in
medium, counted, diluted and plated into Sterilin
plastic petri dishes, 3 replicate dishes for each
point, and incubated for 10 days. At the end of this
period dishes were fixed, stained and colonies
containing >50 cells were counted. A value for the
surviving fraction was estimated by calculating the
mean of the replicate plates for each treatment
volume. The remainder of the cells not used for
plating were assayed for ADM content either by
FCM or organic extraction as described below.
Estimation ofrelative adriamycin uptake
A detailed account of the extraction method was
published by Schwartz (1973). Briefly, 105 cells
from each sample were centrifuged at 200 g for
5min at room temperature, the medium was
removed and 0.2ml of 0.1% solution of ice cold
sodium lauryl sulphate (BDH Chemicals) was
added. The mixture was pipetted to lyse the cells
and 0.2ml of ice cold silver nitrate solution (33%
w/v) added. The samples were then shaken
vigorously for 10min at 4°C using a Gallankemp
flask shaker. Four ml of ice cold isoamyl alcohol
were added to each sample and the samples shaken
for a further 10min. The extracts were centrifuged
at 200g for 5min at room temperature and the
isoamyl alcohol fraction was carefully removed with
a pasteur pipette.
ADM fluorescence from the extracts was
measured using an MPF-4 Perkin Elmer fluorimeter
with excitation at 490nm and analysis between 575
and 595nm. FCM analysis was carried out on the
flow cytometer constructed in these laboratories
(Watson, 1980). Excitation was at 488 nm with
120mW from a Spectra Physics 164-05 Argon ion
laser (Mountain View CA. USA) and fluorescence
emission collected above 550nm using a Barr and
Stroud 550nm long pass filter. All gain settings
were recorded and kept constant within an
experimental protocol. Alignment of the instrument
was achieved before each run using 4.3 um green
fluorescent microbeads (Polysciences California).
Fluorescent profiles were recorded as histograms of
fluorescence intensity versus cell frequency. A
relative value of ADM fluorescence for population
was obtained by calculating the median of the
fluorescence distribution.
Extraction of ADM into an organic solvent is an
established technique and has been shown to give
good recovery from different cell types (Schwartz,
1973). In order to establish that FCM and
extraction will give a similar relationship between
exponentially growing and plateau phase cells the
two techniques were run in parallel.
Exponentially growing and plateau phase cells
were prepared as described above. The growth
medium was removed and 5ml of fresh medium
containing ADM at concentrations of 0, 1, 2, 5, 10,
25 ugADMml-1 were added to the cells. Incubation
was for 1 h at 37°C. The cells were then trypsinised
and resuspended in 5ml of medium, 105 cells were
removed from each sample for extraction of ADM
and the remainder were analysed for ADM by
FCM.
Isodose experiments
Experiments were designed to expose exponentially
growing and plateau phase cells to the same dose
range of ADM in terms of picograms (pg) per cell.
Exponentially growing and plateau phase cultures
were prepared as described previously. Plateau cells
were treated with doses of 0, 1.25, 2.5, 3.75, 6.25pg
per cell, exponentially growing cells were treated
with 0, 0.5, 1, 2, 3, 4pg per cell. The cultures were
incubated for 1 h at 37°C and then assayed for
surviving fraction and ADM content by FCM
analysis as described above.
Results
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Figure 1 (a) FCM measurement of intracellular
ADM fluorescence from exponentially growing EMT6
cells treated with increasing volumes of tissue culture
medium containing 2pg ADMml-. Error bars
represent +s.e. Each point represents the mean of 5
replicate experiments. (b) Surviving fraction of
exponentially growing EMT6 cells treated with
increasing volumes of tissue culture medium
containing 2pg ADMml l. Error bars represent +s.e.
Each point represents the mean of 5 replicate
experiments.
fluorescence distributions from exponentially
growing cells assayed in the flow cytometer as
related to volume of medium at a constant ADM
concentration of 2pgml -1. The median
fluorescence value increases from channel 150 to
330 as the volume increases to 2ml. This is
effectively a two-fold decrease in cell concentration.
Further decrease in cell concentration did not
increase the intracellular ADM fluorescence
substantially beyond a value of 300-350. This
pattern of cellular uptake of ADM and the
resultant fluorescent intensity of the drug was
associated with increased cell killing (Figure 1,
lower panel). A surviving fraction of 0.035 was
obtained by a two-fold dilution of cells; further
dilution did not result in significantly more cell
killing. This reflects the FCM results.
Two methods of ADM estimation were
compared in order to establish that FCM
measurements of ADM fluorescence in
exponentially growing cells and plateau phase cells
were equivalent. Figure 2 shows the result of
comparing ADM fluorescence by the organic
extraction estimation against that by FCM
estimation. Good agreement was found between the
curves for the two proliferative states. These data
provide support for the assumption that the ADM
fluorescence measured by FCM reflects the relative
amount of intracellular ADM in both exponentially
growing and plateau phase EMT6/CC cells.
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Figure 2 Intracellular ADM fluorescence measured
by FCM versus spectrofluorometric measurement of
extracted ADM from EMT6 cells. Open symbols
represent exponentially growing cells, closed symbols
represent plateau phase cells. These data are from one
representative calibration experiment.
Using FCM derived fluorescence as a
measurement of ADM uptake, we compared the
differential cytotoxicity of ADM in exponentially
growing and plateau phase cells. As shown in
Figure 3, plateau phase cells exhibited a decrease in
surviving fraction for a given dose of ADM up to
20pg per 106 cells when compared with
exponentially growing cells, when the surviving
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Figure 3 Surviving fraction of exponentially growing
EMT6 cells (open symbols, 4 replicate experiments)
and plateau phase EMT6 cells (closed symbols, 5
replicate experiments) versus ADM dose represented as
jg 10-6 cells. The square symbols represent data for
which fluorescence emissions were too high to be
recorded on the flow cytometer when set up to record
the emissions from the exponentially growing cells.
C
Figure 4 Surviving fraction data from Figure 3
plotted against intracellular ADM fluorescence as
measured by FCM. Exponentially growing cells are
represented by open symbols (4 replicate experiments),
plateau phase cells by closed symbols (5 replicate
experiments).
fractions were plotted as a function of the exposure
dose of ADM expressed as Mg per 106 cells.
However, when ADM drug levels were expressed as
the intracellular ADM concentration assayed by
FCM, it was apparent that the reverse was true
(Figure 4); viz. that for a given intracellular ADM
concentration, exponentially growing cells had a
much lower value for surviving fraction than
plateau phase cells. For example, at a fluorescence
value of 100 the surviving fraction of exponentially
growing cells was 0.015, compared to 0.42 for
plateau phase cells.
Discussion
Barranco & Novak (1974) reported treating
exponentially growing and plateau phase CHO cells
with between 0 and lOg ADM ml-1 of growth
medium. Their conclusions were that plateau phase
cells had the same shape survival curve as
exponentially growing cells but were less sensitive
to ADM. They made no allowance for the
difference in cell density between the two
proliferative states. Twentyman & Bleehen (1975)
published results from the investigation of the
response of EMT6 exponentially growing and
plateau phase cells to ADM. They used the
convention of presenting surviving fraction plotted
against the concentration of the drug in the
medium and commented that differences in
observed response may be due to drug availability.
However, no experiments were carried out to
investigate whether or not this was true. We have
shown that there is indeed an effect due to drug
availability and cell density. Data in Figure 1 show
that at ADM doses generally used (0-
5pgADMml-1) in experiments when treating cells
in vitro, the cell number can be an important factor
in determining the clonogenic fraction; 2.5 x 105
cells ml-' gave a surviving fraction of 0.025
whereas 106 cells ml-l gave a surviving fraction of
0.2, a difference of one decade, when treated with
medium containing 2 ugml-1 ADM. When
attempting to compare the sensitivities of
clonogenic cells in monolayers of exponentially
growing and plateau phase cultures, where the cell
number present in the latter culture is at least one
hundred times that of the former we now believe
that it is important to take into account the effect
of cell number in relationship to drug dose. Durand
& Olive (1981) have also reported that ADM
uptake is highly dependent on cell density and
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method of cell growth. Consequently we conclude
that it is more representative to express the
exposure drug dose as pg per 106 cells.
Having established how best to represent our
results and that FCM was giving a fair comparison
of ADM levels in exponentially growing and
plateau phase cells, we were able to draw some
conclusions as to the response of the cells in these
two proliferative states to ADM.
A similar range of exposure doses were given to
both exponentially growing and plateau phase cells.
Figure 3 indicates plateau phase cells were more
sensitive over the dose range 0-10pg per 106 cells.
Figure 5 shows that over that dose range a greater
quantity of ADM was taken up by plateau phase
cells. This indicates plateau phase cells have a far
greater ability to accumulate ADM than
exponentially growing cells but are less sensitive to
a change in internal drug concentration. This point
is demonstrated in Figure 4 where, for a given
amount of internal ADM, plateau phase cells are
far less sensitive than exponentially growing cells
and the slope of their survival curve considerably
less than that for exponentially growing cells.
Our results agree with the findings of Bhuyan et
al. (1981) in that intracellular drug concentration
may not account for the sensitivity of the cells to a
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Figure 5 FCM measurement of intracellular ADM
fluorescence (absorbed dose) plotted against exposure
dose of ADM. Open symbols, exponentially growing
cells (4 replicate experiments); closed symbols, plateau
phase cell (5 replicate experiments).
particular agent. Bhuyan et al (1981) found that in
CHO cells treated with the anthracycline, 7-con-0-
MethylnogaroL exponentially growing cells were
more sensitive than plateau phase cells with the
same internal drug concentration. Sutherland et al
(1979) published data from exponentially growing
and plateau phase EMT6 cells in monolayer treated
with ADM and present the results as surviving
fraction against internal drug concentration. They
report only a small difference in sensitivity between
the two proliferative states but they did not treat
the plateau cells with the same range of dose of
ADM as reported in this paper. Our results are
similar to those of Sutherland et al (1979) over the
range of dose of ADM that was used.
The differences in ADM uptake found in
exponentially growing cells and plateau phase cells
are likely to be primarily due to differences in the
membrane permeability/drug export in the two
proliferative states. Cell membrane differences have
been shown to alter the uptake of ADM (Li &
Hahn, 1978) and these data would suggest that
plateau phase cells have more permeable
membranes than exponentially growing cells.
The observation that, for a given amount of
intracellular ADM, exponentially growing cells were
far more sensitive to ADM is less easy to explain.
We have demonstrated that the toxicity of ADM
is not due simply to the total amount of
ADM associated with the cell, therefore the ADM
must be acting on a sensitive target that is
preferentially expressed by exponentially growing
cells, but not plateau phase cells. ADM is thought
to act on several different sites within the cell
(Bachur, 1975) and we have preliminary data
suggesting that up to 45% of the ADM
fluorescence for exponentially growing cells is
associated with RNA (Smith and Chambers,
unpublished data). Since exponentially growing cells
have more RNA than plateau phase cells (Watson
& Chambers, 1977), it is possible that the RNA
content may play a role in ADM cytotoxicity.
Tritton (1982) has shown that the cell surface
may be an important site for the cytotoxic action of
ADM. If this is so the ratio of cell number to drug
concentration will still be a factor in determining
cell survival. However he does not rule out that the
administration of free ADM affects cell viability
through DNA intercalation. We have shown that in
this case it is important to measure intracellular
ADM concentrations in order to draw conclusions
as to the relative sensitivities of cells to the drug.306 S.H. CHAMBERS et al.
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